Athenex Key Executives
This section highlights Athenex's key executives, including their titles and compensation details.
Find Contacts at Athenex
(Showing 0 of )
Athenex Earnings
This section highlights Athenex's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.
$0.20
Stock Price
$2.33M
Market Cap
269
Employees
Buffalo, NY
Location
Financial Statements
Access annual & quarterly financial statements for Athenex, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Revenue | $102.82M | $120.18M | $144.39M | $101.23M | $89.10M |
| Cost of Revenue | $76.12M | $82.41M | $95.36M | $69.62M | $47.01M |
| Gross Profit | $26.70M | $37.77M | $49.04M | $31.61M | $42.09M |
| Gross Profit Ratio | 25.97% | 31.40% | 33.96% | 31.23% | 47.24% |
| Research and Development Expenses | $51.76M | $80.20M | $75.90M | $84.39M | $119.91M |
| General and Administrative Expenses | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $44.88M | $72.55M | $96.86M | $66.75M | $49.01M |
| Other Expenses | $- | $- | $- | $19.71M | $- |
| Operating Expenses | $96.64M | $152.75M | $172.76M | $151.14M | $168.91M |
| Cost and Expenses | $172.76M | $235.16M | $268.11M | $220.76M | $215.92M |
| Interest Income | $363.00K | $227.00K | $874.00K | $1.88M | $- |
| Interest Expense | $25.84M | $20.74M | $11.22M | $6.95M | $1.79M |
| Depreciation and Amortization | $363.00K | $227.00K | $874.00K | $1.88M | $3.27M |
| EBITDA | $-69.57M | $-114.75M | $-122.85M | $-117.65M | $-112.28M |
| EBITDA Ratio | -67.66% | -95.48% | -85.08% | -116.22% | -126.01% |
| Operating Income | $-69.94M | $-114.97M | $-123.72M | $-119.53M | $-126.82M |
| Operating Income Ratio | -68.02% | -95.67% | -85.69% | -118.08% | -142.33% |
| Total Other Income Expenses Net | $-28.69M | $-89.93M | $-20.62M | $-5.07M | $-1.79M |
| Income Before Tax | $-98.63M | $-204.91M | $-144.35M | $-124.61M | $-128.61M |
| Income Before Tax Ratio | -95.92% | -170.50% | -99.97% | -123.09% | -144.34% |
| Income Tax Expense | $347.00K | $-10.60M | $4.09M | $928.00K | $100.00K |
| Net Income | $-98.97M | $-194.31M | $-148.43M | $-125.53M | $-117.44M |
| Net Income Ratio | -96.26% | -161.68% | -102.80% | -124.01% | -131.81% |
| EPS | $-15.13 | $-37.39 | $-34.89 | $-33.90 | $-36.40 |
| EPS Diluted | $-15.13 | $-37.39 | $-34.89 | $-33.90 | $-36.40 |
| Weighted Average Shares Outstanding | 6.54M | 5.20M | 4.25M | 3.70M | 3.23M |
| Weighted Average Shares Outstanding Diluted | 6.54M | 5.20M | 4.25M | 3.70M | 3.23M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 | December 31, 2018 | September 30, 2018 | June 30, 2018 | March 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.06M | $33.53M | $31.52M | $29.72M | $24.94M | $32.30M | $21.92M | $41.02M | $21.81M | $35.48M | $40.17M | $46.94M | $34.36M | $19.36M | $22.20M | $25.31M | $21.27M | $18.43M | $11.56M | $37.84M |
| Cost of Revenue | $18.18M | $27.74M | $23.09M | $23.30M | $20.69M | $25.64M | $19.66M | $16.41M | $18.27M | $24.51M | $33.01M | $19.57M | $15.70M | $17.07M | $16.94M | $19.90M | $14.27M | $11.96M | $9.44M | $11.33M |
| Gross Profit | $6.88M | $5.79M | $8.42M | $6.43M | $4.24M | $6.65M | $2.26M | $24.62M | $3.54M | $10.97M | $7.17M | $27.36M | $18.66M | $2.29M | $5.25M | $5.41M | $7.00M | $6.46M | $2.12M | $26.51M |
| Gross Profit Ratio | 27.40% | 17.30% | 26.70% | 21.60% | 17.00% | 20.60% | 10.30% | 60.00% | 16.24% | 30.91% | 17.84% | 58.30% | 54.30% | 11.84% | 23.67% | 21.36% | 32.91% | 35.07% | 18.35% | 70.07% |
| Research and Development Expenses | $16.40M | $9.21M | $13.09M | $13.99M | $18.27M | $17.73M | $21.13M | $23.07M | $18.31M | $18.39M | $22.02M | $17.19M | $21.82M | $19.59M | $18.51M | $24.48M | $20.83M | $51.20M | $26.57M | $21.30M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $7.20M | $9.44M | $17.17M | $14.94M | $6.41M | $22.79M | $21.23M | $22.12M | $31.40M | $22.22M | $17.49M | $25.75M | $18.11M | $16.28M | $17.17M | $15.19M | $11.62M | $11.49M | $12.82M | $13.08M |
| Other Expenses | $79.00K | $- | $- | $- | $2.46M | $-2.46M | $- | $- | $- | $- | $- | $15.58M | $- | $564.00K | $3.46M | $5.55M | $- | $- | $- | $7.87M |
| Operating Expenses | $23.60M | $18.65M | $30.27M | $28.93M | $27.14M | $38.07M | $42.36M | $45.19M | $49.71M | $40.61M | $39.50M | $42.94M | $39.93M | $35.87M | $35.68M | $39.66M | $32.45M | $62.70M | $39.39M | $34.38M |
| Cost and Expenses | $41.78M | $46.39M | $53.36M | $52.22M | $47.83M | $63.71M | $62.02M | $61.59M | $67.97M | $65.12M | $72.51M | $62.51M | $55.64M | $52.94M | $52.62M | $59.56M | $46.72M | $74.66M | $48.83M | $45.71M |
| Interest Income | $132.00K | $109.00K | $46.00K | $77.00K | $27.00K | $39.00K | $132.00K | $29.00K | $164.00K | $112.00K | $185.00K | $413.00K | $473.00K | $650.00K | $- | $- | $- | $- | $- | $- |
| Interest Expense | $10.75M | $6.27M | $4.31M | $4.52M | $5.05M | $5.10M | $5.68M | $4.91M | $4.39M | $3.60M | $1.56M | $1.67M | $1.70M | $1.75M | $1.28M | $1.47M | $1.33M | $1.06M | $368.00K | $227.00K |
| Depreciation and Amortization | $132.00K | $855.00K | $46.00K | $949.00K | $1.01M | $1.20M | $1.19M | $1.27M | $1.28M | $1.09M | $1.03M | $1.09M | $1.01M | $1.00M | $928.00K | $879.00K | $845.00K | $759.00K | $797.00K | $868.00K |
| EBITDA | $-16.59M | $-12.00M | $-21.80M | $-21.55M | $-98.31M | $-29.49M | $-38.43M | $-18.71M | $-43.81M | $-31.03M | $-37.74M | $-13.79M | $-19.11M | $-31.90M | $-29.42M | $-32.38M | $-24.55M | $-44.38M | $-35.64M | $-6.51M |
| EBITDA Ratio | -66.19% | -35.80% | -69.16% | -72.49% | -394.24% | -91.32% | -175.30% | -45.62% | -200.91% | -87.47% | -93.96% | -29.38% | -55.61% | -164.73% | -132.54% | -127.96% | -115.42% | -240.85% | -308.20% | -17.21% |
| Operating Income | $-16.72M | $-12.86M | $-21.84M | $-22.50M | $-99.32M | $-33.87M | $-40.10M | $-20.57M | $-46.17M | $-29.64M | $-32.34M | $-15.58M | $-21.27M | $-33.58M | $-30.42M | $-34.26M | $-25.45M | $-56.23M | $-37.27M | $-7.87M |
| Operating Income Ratio | -66.71% | -38.35% | -69.30% | -75.68% | -398.31% | -104.88% | -182.90% | -50.14% | -211.70% | -83.56% | -80.49% | -33.19% | -61.92% | -173.40% | -137.05% | -135.37% | -119.63% | -305.16% | -322.24% | -20.81% |
| Total Other Income Expenses Net | $-12.31M | $-6.16M | $-19.00K | $-7.95M | $2.43M | $-2.60M | $-5.55M | $-4.88M | $-4.22M | $-6.53M | $-8.61M | $-1.26M | $-1.23M | $-1.09M | $-1.28M | $-1.47M | $-1.33M | $-1.06M | $368.00K | $227.00K |
| Income Before Tax | $-29.03M | $-19.02M | $-24.05M | $-30.44M | $-97.34M | $-36.47M | $-45.65M | $-25.45M | $-50.39M | $-36.17M | $-40.95M | $-16.84M | $-22.50M | $-34.67M | $-31.70M | $-35.73M | $-26.78M | $-57.29M | $-36.90M | $-7.65M |
| Income Before Tax Ratio | -115.81% | -56.73% | -76.32% | -102.41% | -390.34% | -112.93% | -208.23% | -62.03% | -231.06% | -101.97% | -101.92% | -35.87% | -65.49% | -179.06% | -142.81% | -141.19% | -125.88% | -310.90% | -319.06% | -20.21% |
| Income Tax Expense | $-258.00K | $596.00K | $-19.00K | $28.00K | $15.00K | $262.00K | $-11.04M | $154.00K | $8.00K | $1.09M | $106.00K | $2.88M | $-91.00K | $114.00K | $405.00K | $500.00K | $386.00K | $-30.00K | $51.00K | $-307.00K |
| Net Income | $-28.77M | $-19.62M | $-24.03M | $-30.47M | $-97.35M | $-36.06M | $-34.27M | $-25.05M | $-49.49M | $-36.81M | $-40.45M | $-19.43M | $-21.73M | $-34.76M | $-32.03M | $-35.23M | $-27.11M | $-46.17M | $-36.86M | $-7.30M |
| Net Income Ratio | -114.78% | -58.50% | -76.26% | -102.51% | -390.40% | -111.64% | -156.34% | -61.06% | -226.95% | -103.75% | -100.69% | -41.40% | -63.23% | -179.50% | -144.30% | -139.22% | -127.46% | -250.55% | -318.71% | -19.29% |
| EPS | $-3.60 | $-2.81 | $-4.25 | $-5.51 | $-17.80 | $-6.60 | $-6.63 | $-5.36 | $-10.61 | $-8.79 | $-9.92 | $-4.77 | $-5.53 | $-8.99 | $-8.76 | $-10.52 | $-8.20 | $-13.91 | $-11.64 | $-2.37 |
| EPS Diluted | $-3.60 | $-2.81 | $-4.25 | $-5.51 | $-17.80 | $-6.60 | $-6.63 | $-5.36 | $-10.61 | $-8.79 | $-9.92 | $-4.77 | $-5.53 | $-8.99 | $-8.76 | $-10.52 | $-8.20 | $-13.91 | $-11.64 | $-2.37 |
| Weighted Average Shares Outstanding | 7.98M | 6.97M | 5.65M | 5.53M | 5.47M | 5.46M | 5.17M | 4.67M | 4.67M | 4.19M | 4.08M | 4.08M | 3.93M | 3.86M | 3.66M | 3.35M | 3.31M | 3.32M | 3.17M | 3.08M |
| Weighted Average Shares Outstanding Diluted | 7.98M | 6.97M | 5.65M | 5.53M | 5.47M | 5.46M | 5.17M | 4.67M | 4.67M | 4.19M | 4.08M | 4.08M | 3.93M | 3.86M | 3.66M | 3.35M | 3.31M | 3.32M | 3.17M | 3.08M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $35.62M | $51.70M | $86.09M | $127.67M | $49.79M |
| Short Term Investments | $1.07M | $10.21M | $138.64M | $33.14M | $57.63M |
| Cash and Short Term Investments | $36.69M | $61.91M | $224.72M | $160.81M | $107.42M |
| Net Receivables | $27.86M | $26.64M | $23.60M | $16.69M | $12.95M |
| Inventory | $42.65M | $34.69M | $28.85M | $32.63M | $28.79M |
| Other Current Assets | $22.90M | $26.66M | $31.29M | $20.79M | $21.66M |
| Total Current Assets | $124.93M | $61.91M | $291.96M | $230.93M | $170.82M |
| Property Plant Equipment Net | $6.04M | $34.22M | $42.31M | $31.97M | $11.45M |
| Goodwill | $- | $- | $38.89M | $38.51M | $37.49M |
| Intangible Assets | $72.11M | $71.90M | $10.22M | $8.52M | $10.85M |
| Goodwill and Intangible Assets | $72.11M | $71.90M | $49.11M | $47.03M | $48.34M |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $486.00K |
| Other Non-Current Assets | $971.00K | $-106.12M | $950.00K | $- | $- |
| Total Non-Current Assets | $79.13M | $134.05M | $92.37M | $79.01M | $60.28M |
| Other Assets | $- | $71.49M | $- | $- | $- |
| Total Assets | $204.06M | $267.45M | $384.33M | $309.93M | $231.09M |
| Account Payables | $33.68M | $16.74M | $18.67M | $23.33M | $13.00M |
| Short Term Debt | $39.21M | $49.79M | $5.20M | $3.89M | $961.00K |
| Tax Payables | $1.75M | $1.80M | $1.95M | $187.00K | $- |
| Deferred Revenue | $2.82M | $3.29M | $1.15M | $218.00K | $190.00K |
| Other Current Liabilities | $37.41M | $24.42M | $35.18M | $43.90M | $37.53M |
| Total Current Liabilities | $114.88M | $96.05M | $62.14M | $71.53M | $51.68M |
| Long Term Debt | $3.14M | $150.34M | $152.93M | $59.99M | $45.80M |
| Deferred Revenue Non-Current | $- | $-28.87M | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $1.75M | $1.75M | $56.00K | $- | $- |
| Other Non-Current Liabilities | $108.46M | $27.12M | $3.85M | $2.56M | $4.85M |
| Total Non-Current Liabilities | $113.36M | $150.34M | $156.84M | $62.55M | $50.65M |
| Other Liabilities | $-24.18M | $37.74M | $165.35M | $175.85M | $- |
| Total Liabilities | $204.06M | $284.13M | $384.33M | $309.93M | $102.33M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $9.00K | $111.00K | $95.00K | $83.00K | $69.00K |
| Retained Earnings | $-1.02B | $-913.41M | $-713.64M | $-567.47M | $-443.72M |
| Accumulated Other Comprehensive Income Loss | $887.00K | $-487.00K | $-1.13M | $-635.00K | $-656.00K |
| Other Total Stockholders Equity | $1.01B | $913.79M | $894.46M | $756.24M | $583.66M |
| Total Stockholders Equity | $-6.51M | $-913.79M | $179.78M | $188.22M | $139.35M |
| Total Equity | $-24.18M | $-930.47M | $165.35M | $175.85M | $128.77M |
| Total Liabilities and Stockholders Equity | $204.06M | $267.45M | $384.33M | $309.93M | $231.09M |
| Minority Interest | $-17.68M | $-16.68M | $-14.43M | $-12.37M | $-10.59M |
| Total Liabilities and Total Equity | $204.06M | $267.45M | $384.33M | $309.93M | $231.09M |
| Total Investments | $1.07M | $10.21M | $138.64M | $33.14M | $57.63M |
| Total Debt | $42.36M | $150.34M | $158.13M | $63.88M | $46.76M |
| Net Debt | $6.74M | $98.64M | $72.04M | $-63.80M | $-3.03M |
Balance Sheet Charts
| Breakdown | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 | December 31, 2018 | September 30, 2018 | June 30, 2018 | March 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $35.62M | $35.19M | $35.96M | $27.22M | $35.20M | $73.59M | $76.94M | $47.98M | $69.59M | $143.56M | $105.90M | $71.98M | $127.67M | $61.48M | $96.73M | $71.00M | $49.79M | $51.11M | $14.07M | $39.22M |
| Short Term Investments | $1.07M | $1.03M | $1.19M | $10.23M | $10.21M | $14.92M | $53.28M | $123.19M | $138.64M | $84.75M | $10.41M | $41.72M | $33.14M | $42.27M | $43.72M | $341.00K | $57.63M | $90.31M | $66.59M | $67.26M |
| Cash and Short Term Investments | $36.69M | $36.22M | $37.15M | $37.46M | $45.41M | $88.51M | $130.22M | $171.17M | $208.22M | $228.31M | $116.31M | $113.70M | $160.81M | $103.75M | $140.45M | $71.34M | $107.42M | $141.42M | $80.66M | $106.48M |
| Net Receivables | $27.86M | $32.91M | $33.82M | $29.61M | $26.64M | $33.76M | $22.22M | $20.19M | $23.60M | $42.99M | $38.62M | $51.42M | $16.69M | $17.17M | $9.56M | $20.58M | $12.95M | $7.07M | $5.14M | $7.84M |
| Inventory | $42.65M | $42.04M | $37.85M | $41.25M | $34.69M | $31.58M | $29.77M | $26.32M | $28.85M | $29.61M | $31.14M | $35.73M | $32.63M | $28.45M | $27.24M | $25.19M | $28.79M | $25.23M | $21.80M | $18.57M |
| Other Current Assets | $22.90M | $15.53M | $-57.85M | $23.27M | $26.66M | $30.99M | $30.88M | $33.47M | $31.29M | $23.30M | $30.53M | $17.05M | $20.79M | $64.17M | $72.43M | $33.57M | $21.66M | $13.98M | $11.95M | $7.20M |
| Total Current Assets | $124.93M | $126.71M | $37.15M | $131.59M | $133.40M | $184.84M | $213.09M | $251.15M | $291.96M | $324.20M | $216.61M | $217.90M | $230.93M | $213.54M | $249.69M | $150.68M | $170.82M | $187.70M | $119.55M | $140.09M |
| Property Plant Equipment Net | $6.04M | $8.35M | $9.08M | $32.66M | $34.22M | $58.43M | $52.70M | $49.24M | $42.31M | $36.31M | $34.71M | $32.88M | $31.97M | $27.79M | $25.29M | $21.68M | $11.45M | $11.17M | $10.40M | $10.37M |
| Goodwill | $- | $- | $- | $- | $- | $67.62M | $69.22M | $38.84M | $38.89M | $38.69M | $38.50M | $38.48M | $38.51M | $37.29M | $37.53M | $37.59M | $37.49M | $37.50M | $37.66M | $37.95M |
| Intangible Assets | $72.11M | $72.17M | $72.47M | $71.57M | $71.90M | $73.89M | $72.78M | $9.48M | $10.22M | $9.56M | $8.02M | $8.53M | $8.52M | $8.97M | $9.77M | $10.36M | $10.85M | $7.25M | $7.74M | $8.28M |
| Goodwill and Intangible Assets | $72.11M | $72.17M | $72.47M | $71.57M | $71.90M | $141.50M | $142.00M | $48.32M | $49.11M | $48.25M | $46.51M | $47.01M | $47.03M | $46.27M | $47.30M | $47.95M | $48.34M | $44.76M | $45.40M | $46.22M |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-486.00K | $399.00K | $447.00K | $411.00K |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $486.00K | $437.00K | $416.00K | $442.00K |
| Other Non-Current Assets | $971.00K | $21.12M | $-55.01M | $1.05M | $27.93M | $1.13M | $1.17M | $947.00K | $950.00K | $877.00K | $222.00K | $- | $- | $- | $- | $- | $486.00K | $- | $1.07M | $- |
| Total Non-Current Assets | $79.13M | $101.64M | $26.54M | $105.27M | $134.05M | $201.06M | $195.87M | $98.51M | $92.37M | $85.44M | $81.45M | $79.89M | $79.01M | $74.05M | $72.59M | $69.63M | $60.28M | $56.77M | $57.73M | $57.44M |
| Other Assets | $- | $- | $158.19M | $- | $16.68M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $204.06M | $228.35M | $221.89M | $236.86M | $284.13M | $385.89M | $408.96M | $349.66M | $384.33M | $409.64M | $298.05M | $297.79M | $309.93M | $287.60M | $322.27M | $220.31M | $231.09M | $244.47M | $177.29M | $197.53M |
| Account Payables | $33.68M | $25.07M | $21.40M | $16.61M | $16.74M | $22.88M | $19.47M | $15.86M | $18.67M | $14.87M | $15.95M | $18.39M | $23.33M | $16.21M | $15.58M | $20.39M | $13.00M | $12.69M | $14.34M | $16.15M |
| Short Term Debt | $39.21M | $16.95M | $25.82M | $27.22M | $49.79M | $10.53M | $7.84M | $5.13M | $5.20M | $4.58M | $3.82M | $3.66M | $3.89M | $3.77M | $4.61M | $4.79M | $961.00K | $978.00K | $1.05M | $1.24M |
| Tax Payables | $1.75M | $1.68M | $1.67M | $1.92M | $1.80M | $1.65M | $1.55M | $1.86M | $1.95M | $2.81M | $5.23M | $5.28M | $187.00K | $256.00K | $201.00K | $192.00K | $- | $- | $- | $- |
| Deferred Revenue | $2.82M | $2.79M | $2.78M | $3.28M | $3.29M | $3.21M | $1.08M | $1.29M | $1.15M | $328.00K | $97.00K | $75.00K | $218.00K | $20.07M | $20.16M | $131.00K | $190.00K | $364.00K | $5.53M | $5.74M |
| Other Current Liabilities | $37.41M | $38.41M | $38.51M | $31.76M | $24.42M | $35.26M | $32.98M | $25.56M | $35.18M | $43.96M | $41.82M | $49.38M | $43.90M | $49.67M | $54.77M | $42.25M | $37.53M | $28.06M | $26.83M | $13.51M |
| Total Current Liabilities | $114.88M | $84.90M | $90.17M | $80.78M | $96.05M | $73.53M | $62.92M | $49.70M | $62.14M | $66.55M | $66.91M | $76.80M | $71.53M | $89.97M | $95.31M | $67.75M | $51.68M | $42.10M | $47.75M | $36.63M |
| Long Term Debt | $3.14M | $25.68M | $51.94M | $106.51M | $107.95M | $147.86M | $150.59M | $153.10M | $152.93M | $128.17M | $102.24M | $60.12M | $59.99M | $60.26M | $57.12M | $54.37M | $45.80M | $45.55M | $449.00K | $428.00K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $1.75M | $1.75M | $1.75M | $1.75M | $1.75M | $1.82M | $1.83M | $58.00K | $56.00K | $53.00K | $51.00K | $48.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $108.46M | $108.78M | $84.42M | $27.01M | $27.25M | $26.80M | $23.73M | $3.67M | $3.85M | $2.63M | $2.61M | $2.58M | $2.56M | $2.54M | $2.63M | $2.60M | $4.85M | $4.76M | $4.68M | $4.39M |
| Total Non-Current Liabilities | $113.36M | $136.21M | $138.11M | $135.28M | $136.95M | $176.48M | $176.15M | $156.83M | $156.84M | $130.85M | $104.90M | $62.76M | $62.55M | $62.80M | $59.75M | $56.98M | $50.65M | $50.31M | $5.13M | $4.82M |
| Other Liabilities | $-24.18M | $- | $11.02M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $204.06M | $221.11M | $239.29M | $216.06M | $233.00M | $250.01M | $239.08M | $206.53M | $218.98M | $197.41M | $171.81M | $139.55M | $134.08M | $152.77M | $155.07M | $124.73M | $102.33M | $92.41M | $52.88M | $41.45M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $9.00K | $159.00K | $119.00K | $113.00K | $111.00K | $111.00K | $111.00K | $95.00K | $95.00K | $95.00K | $83.00K | $83.00K | $83.00K | $79.00K | $79.00K | $69.00K | $69.00K | $68.00K | $65.00K | $65.00K |
| Retained Earnings | $-1.02B | $-982.66M | $-962.99M | $-930.83M | $-913.41M | $-809.02M | $-772.97M | $-738.69M | $-713.64M | $-664.15M | $-627.35M | $-586.89M | $-567.47M | $-545.74M | $-510.98M | $-478.95M | $-443.72M | $-416.60M | $-370.43M | $-333.57M |
| Accumulated Other Comprehensive Income Loss | $887.00K | $2.99M | $1.47M | $75.00K | $-487.00K | $-1.04M | $-1.12M | $-841.00K | $-1.13M | $-1.03M | $-1.07M | $-1.14M | $-635.00K | $-423.00K | $-114.00K | $415.00K | $-656.00K | $-620.00K | $-29.00K | $537.00K |
| Other Total Stockholders Equity | $1.01B | $1.00B | $973.33M | $968.63M | $964.92M | $961.83M | $959.18M | $897.54M | $894.46M | $890.84M | $767.64M | $758.85M | $756.24M | $692.59M | $689.88M | $585.63M | $583.66M | $579.75M | $494.25M | $488.41M |
| Total Stockholders Equity | $-6.51M | $24.84M | $11.94M | $37.99M | $51.13M | $151.88M | $185.20M | $158.10M | $179.78M | $225.76M | $139.31M | $170.90M | $188.22M | $146.51M | $178.86M | $107.16M | $139.35M | $162.59M | $123.86M | $155.44M |
| Total Equity | $-24.18M | $7.24M | $-5.47M | $20.80M | $51.13M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Stockholders Equity | $204.06M | $228.35M | $221.89M | $236.86M | $284.13M | $385.89M | $408.96M | $349.66M | $398.76M | $409.64M | $298.05M | $297.79M | $322.30M | $287.60M | $322.27M | $220.31M | $241.68M | $244.47M | $177.29M | $197.53M |
| Minority Interest | $-17.68M | $-17.61M | $-17.41M | $-17.19M | $- | $-16.00M | $-15.32M | $-14.98M | $- | $-13.52M | $-13.06M | $-12.66M | $- | $-11.69M | $-11.66M | $-11.58M | $- | $-10.54M | $553.00K | $644.00K |
| Total Liabilities and Total Equity | $204.06M | $228.35M | $221.89M | $236.86M | $284.13M | $385.89M | $408.96M | $349.66M | $398.76M | $409.64M | $298.05M | $297.79M | $322.30M | $287.60M | $322.27M | $220.31M | $241.68M | $244.47M | $177.29M | $197.53M |
| Total Investments | $1.07M | $1.03M | $1.19M | $10.23M | $10.21M | $14.92M | $53.28M | $123.19M | $138.64M | $84.75M | $10.41M | $41.72M | $33.14M | $42.27M | $43.72M | $341.00K | $57.63M | $90.71M | $67.04M | $67.67M |
| Total Debt | $42.36M | $42.63M | $77.75M | $133.74M | $157.74M | $158.39M | $158.43M | $158.23M | $158.13M | $132.75M | $106.06M | $63.78M | $63.88M | $64.03M | $61.73M | $59.16M | $46.76M | $46.53M | $1.50M | $1.66M |
| Net Debt | $6.74M | $7.44M | $41.79M | $106.51M | $122.54M | $84.80M | $81.49M | $110.25M | $88.54M | $-10.81M | $158.00K | $-8.20M | $-63.80M | $2.55M | $-35.00M | $-11.84M | $-3.03M | $-4.58M | $-12.57M | $-37.55M |
Annual Cash Flow
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Net Income | $-98.97M | $-194.31M | $-148.43M | $-125.53M | $-128.71M |
| Depreciation and Amortization | $2.32M | $4.68M | $4.49M | $3.82M | $3.27M |
| Deferred Income Tax | $- | $-10.85M | $56.00K | $486.00K | $-365.00K |
| Stock Based Compensation | $6.33M | $9.21M | $10.85M | $9.88M | $11.01M |
| Change in Working Capital | $11.78M | $-23.77M | $-20.00M | $12.63M | $-27.15M |
| Accounts Receivables | $- | $19.22M | $13.06M | $-19.34M | $-3.53M |
| Inventory | $-19.59M | $-5.90M | $3.78M | $-3.84M | $-12.23M |
| Accounts Payables | $35.93M | $-19.22M | $-13.06M | $19.34M | $3.53M |
| Other Working Capital | $-4.57M | $-17.87M | $-23.79M | $16.47M | $-14.92M |
| Other Non Cash Items | $3.54M | $72.65M | $21.79M | $1.26M | $32.56M |
| Net Cash Provided by Operating Activities | $-75.01M | $-142.38M | $-131.24M | $-97.46M | $-109.39M |
| Investments in Property Plant and Equipment | $-2.06M | $-10.54M | $-13.47M | $-17.75M | $-3.43M |
| Acquisitions Net | $- | $1.53M | $214.00K | $853.00K | $110.00K |
| Purchases of Investments | $-9.09M | $-68.67M | $-161.85M | $-74.70M | $-113.26M |
| Sales Maturities of Investments | $18.68M | $197.61M | $56.34M | $99.09M | $67.73M |
| Other Investing Activities | $50.37M | $-14.94M | $-214.00K | $- | $-110.00K |
| Net Cash Used for Investing Activities | $57.90M | $104.98M | $-118.97M | $7.50M | $-48.96M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $29.18M | $1.34M | $126.98M | $161.08M | $123.13M |
| Common Stock Repurchased | $-1.74M | $-79.00K | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $2.37M | $2.46M | $209.43M | $167.45M | $169.03M |
| Net Cash Used Provided by Financing Activities | $1.56M | $2.46M | $209.43M | $167.45M | $169.03M |
| Effect of Forex Changes on Cash | $-534.00K | $548.00K | $-799.00K | $389.00K | $-175.00K |
| Net Change in Cash | $-16.08M | $-34.38M | $-41.59M | $77.88M | $10.51M |
| Cash at End of Period | $35.62M | $51.70M | $86.09M | $127.67M | $49.79M |
| Cash at Beginning of Period | $51.70M | $86.09M | $127.67M | $49.79M | $39.28M |
| Operating Cash Flow | $-75.01M | $-142.38M | $-131.24M | $-97.46M | $-109.39M |
| Capital Expenditure | $-2.06M | $-10.54M | $-13.47M | $-17.75M | $-3.43M |
| Free Cash Flow | $-77.07M | $-152.91M | $-144.71M | $-115.21M | $-112.82M |
Cash Flow Charts
| Breakdown | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 | December 31, 2018 | September 30, 2018 | June 30, 2018 | March 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-25.78M | $-19.92M | $-22.80M | $-30.47M | $-97.35M | $-36.74M | $-34.62M | $-25.60M | $-50.40M | $-37.27M | $-41.05M | $-19.72M | $-22.41M | $-34.79M | $-32.10M | $-36.23M | $-27.16M | $-57.26M | $-36.95M | $-7.34M |
| Depreciation and Amortization | $106.00K | $746.00K | $598.00K | $872.00K | $1.01M | $1.20M | $1.19M | $1.27M | $1.28M | $1.09M | $1.03M | $1.09M | $1.01M | $1.00M | $928.00K | $879.00K | $845.00K | $759.00K | $797.00K | $868.00K |
| Deferred Income Tax | $-19 | $- | $19 | $- | $-67.00K | $159.00K | $-10.94M | $2.00K | $3.00K | $2.00K | $3.00K | $48.00K | $- | $- | $- | $486.00K | $-49.00K | $-21.00K | $26.00K | $-321.00K |
| Stock Based Compensation | $1.44M | $1.41M | $1.60M | $1.87M | $1.88M | $2.65M | $2.44M | $2.23M | $2.85M | $2.69M | $3.05M | $2.26M | $2.66M | $2.15M | $3.30M | $1.78M | $2.35M | $2.42M | $3.54M | $2.70M |
| Change in Working Capital | $828.00K | $2.05M | $3.94M | $4.96M | $-9.88M | $-6.23M | $906.00K | $-8.56M | $2.00M | $2.74M | $4.91M | $-29.65M | $-4.86M | $-5.19M | $22.82M | $-141.00K | $-10.55M | $-12.99M | $5.13M | $-8.74M |
| Accounts Receivables | $- | $- | $- | $-15.10M | $19.22M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $-4.60M | $-4.19M | $-4.23M | $-6.57M | $-3.17M | $-1.81M | $-3.44M | $2.52M | $759.00K | $1.54M | $4.59M | $-3.10M | $-4.18M | $-1.21M | $-2.05M | $3.60M | $-3.56M | $-3.43M | $-3.23M | $-2.01M |
| Accounts Payables | $35.93M | $- | $- | $15.10M | $-19.22M | $- | $- | $-12.32M | $-13.06M | $- | $- | $4.43M | $19.34M | $- | $- | $15.80M | $3.53M | $- | $- | $-7.85M |
| Other Working Capital | $-30.50M | $6.24M | $8.17M | $11.53M | $-6.71M | $-4.42M | $4.35M | $1.24M | $14.30M | $1.20M | $322.00K | $-30.98M | $-20.03M | $-3.98M | $24.87M | $-19.54M | $-10.52M | $-9.56M | $8.36M | $1.12M |
| Other Non Cash Items | $9.01M | $-554.00K | $-3.80M | $-1.13M | $65.99M | $4.08M | $1.80M | $779.00K | $10.11M | $3.73M | $7.53M | $429.00K | $264.00K | $481.00K | $256.00K | $257.00K | $489.00K | $29.81M | $2.15M | $106.00K |
| Net Cash Provided by Operating Activities | $-14.39M | $-16.27M | $-20.46M | $-23.89M | $-38.41M | $-34.88M | $-39.21M | $-29.88M | $-34.16M | $-27.02M | $-24.52M | $-45.55M | $-23.34M | $-36.35M | $-4.80M | $-32.97M | $-34.07M | $-37.29M | $-25.30M | $-12.73M |
| Investments in Property Plant and Equipment | $56.00K | $-1.09M | $-838.00K | $-190.00K | $8.80M | $-6.74M | $-3.62M | $-8.43M | $-6.68M | $-2.14M | $-2.85M | $-1.80M | $-5.06M | $-3.62M | $-3.97M | $-5.09M | $-930.00K | $-866.00K | $-458.00K | $-1.18M |
| Acquisitions Net | $- | $- | $- | $- | $101.00K | $- | $500.00K | $1.09M | $131.00K | $- | $- | $64.00K | $- | $- | $- | $- | $110.00K | $- | $- | $- |
| Purchases of Investments | $- | $401.00K | $- | $-9.49M | $- | $-1.07M | $-11.82M | $-55.78M | $-63.89M | $-74.39M | $- | $-23.57M | $-17.68M | $-13.55M | $-43.46M | $- | $-2.65M | $-39.52M | $-3.83M | $-67.26M |
| Sales Maturities of Investments | $50.00K | $-343.00K | $9.49M | $9.49M | $5.21M | $39.44M | $81.70M | $71.25M | $10.00M | $- | $31.43M | $14.92M | $26.80M | $15.00M | $- | $57.29M | $35.75M | $15.81M | $4.54M | $11.63M |
| Other Investing Activities | $12.40M | $220.00K | $-326.00K | $38.07M | $-15.49M | $- | $925.00K | $-1.09M | $-131.00K | $- | $- | $-64.00K | $853.00K | $- | $- | $- | $-110.00K | $- | $- | $- |
| Net Cash Used for Investing Activities | $12.51M | $-810.00K | $8.32M | $37.88M | $-1.38M | $31.63M | $67.69M | $7.04M | $-60.57M | $-76.53M | $28.58M | $-10.45M | $4.91M | $-2.18M | $-47.43M | $52.20M | $32.16M | $-24.57M | $247.00K | $-56.80M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $3.60M | $20.92M | $2.97M | $1.70M | $1.21M | $- | $- | $- | $211.00K | $126.50M | $- | $- | $60.71M | $- | $100.37M | $- | $468.00K | $50.00M | $- | $72.67M |
| Common Stock Repurchased | $-1.46M | $-272.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $910.00K | $20.78M | $6.06M | $-25.37M | $1.11M | $-97.00K | $695.00K | $754.00K | $24.10M | $143.75M | $40.84M | $732.00K | $59.40M | $3.35M | $103.72M | $976.00K | $671.00K | $99.27M | $118.00K | $68.98M |
| Net Cash Used Provided by Financing Activities | $103.00K | $20.78M | $6.06M | $-25.38M | $1.11M | $-97.00K | $695.00K | $754.00K | $24.10M | $143.75M | $40.84M | $732.00K | $59.40M | $3.35M | $103.72M | $976.00K | $671.00K | $99.27M | $118.00K | $68.98M |
| Effect of Forex Changes on Cash | $-3.01M | $751.00K | $1.07M | $654.00K | $289.00K | $-8.00K | $-211.00K | $478.00K | $-598.00K | $202.00K | $24.00K | $-427.00K | $-203.00K | $-123.00K | $-291.00K | $1.01M | $-75.00K | $-367.00K | $-211.00K | $478.00K |
| Net Change in Cash | $-4.79M | $4.45M | $-5.01M | $-10.73M | $-38.39M | $-3.35M | $28.96M | $-21.61M | $-71.22M | $40.41M | $44.92M | $-55.69M | $40.77M | $-35.29M | $51.20M | $21.21M | $-1.31M | $37.04M | $-25.15M | $-67.00K |
| Cash at End of Period | $35.62M | $40.41M | $35.96M | $40.97M | $51.70M | $90.09M | $93.44M | $64.48M | $86.09M | $157.31M | $116.90M | $71.98M | $127.67M | $86.91M | $122.20M | $71.00M | $49.79M | $51.11M | $14.07M | $39.22M |
| Cash at Beginning of Period | $40.41M | $35.96M | $40.97M | $51.70M | $90.09M | $93.44M | $64.48M | $86.09M | $157.31M | $116.90M | $71.98M | $127.67M | $86.91M | $122.20M | $71.00M | $49.79M | $51.11M | $14.07M | $39.22M | $39.28M |
| Operating Cash Flow | $-14.39M | $-16.27M | $-20.46M | $-23.89M | $-38.41M | $-34.88M | $-39.21M | $-29.88M | $-34.16M | $-27.02M | $-24.52M | $-45.55M | $-23.34M | $-36.35M | $-4.80M | $-32.97M | $-34.07M | $-37.29M | $-25.30M | $-12.73M |
| Capital Expenditure | $56.00K | $-1.09M | $-838.00K | $-190.00K | $8.80M | $-6.74M | $-3.62M | $-8.43M | $-6.68M | $-2.14M | $-2.85M | $-1.80M | $-5.06M | $-3.62M | $-3.97M | $-5.09M | $-930.00K | $-866.00K | $-458.00K | $-1.18M |
| Free Cash Flow | $-14.34M | $-17.36M | $-21.30M | $-24.08M | $-29.61M | $-41.61M | $-42.83M | $-38.30M | $-40.83M | $-29.16M | $-27.37M | $-47.34M | $-28.40M | $-39.97M | $-8.78M | $-38.06M | $-35.00M | $-38.15M | $-25.76M | $-13.90M |
Athenex Dividends
Explore Athenex's dividend history, including dividend yield, payout ratio, and historical payments.
Athenex News
Read the latest news about Athenex, including recent articles, headlines, and updates.
Why Is Athenex (ATNX) Stock Down 54% Today?
Athenex (NASDAQ: ATNX ) stock is falling on Monday after the company announced an agreement with lenders to pursue an expedited sales process. According to a press release from the company, this agreement has it expecting to complete the process by July 1, 2023.
Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process
To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations and Fulfill APD Customer Orders During Process BUFFALO, N.Y., May 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX) (“Athenex” or the “Company”), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that, following an ongoing strategic review, it has reached agreement with its lenders to move forward with an expedited sales process of the Company's assets across its primary businesses: Athenex Pharmaceutical Division (“APD”), Orascovery, and Cell Therapy.
Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO
SAN FRANCISCO , May 1, 2023 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (Quantum Leap) and Athenex, Inc. (Nasdaq: ATNX) will present the findings of the I-SPY 2 TRIAL evaluation of Athenex's oral paclitaxel plus encequidar in combination with GSK's dostarlimab in the neoadjuvant setting at this year's American Society of Clinical Oncology (ASCO) conference. Athenex, a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions collaborated with GSK and Quantum Leap in two study arms of the I-SPY 2 TRIAL.
Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Launch of a Generic Version of Magnesium Sulfate in Water for Injection, in Non-PVC, Single-Patient Use Containers by Their Partner Athenex Pharmaceutical Division (APD)
MINNETONKA, Minn.--(BUSINESS WIRE)--Milla Pharmaceuticals Inc., a subsidiary of the Alter Pharma Group, announced that its partner, Athenex Pharmaceutical Division (APD), has just started to commercialize its abbreviated new drug application (ANDA) approval from the U.S.
Athenex Announces a Reverse Stock Split
BUFFALO, N.Y., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will effect a 1-for-20 reverse stock split of its issued common stock, effective at 12:01 a.m. Eastern Time on February 15, 2023. Beginning tomorrow, February 15, 2023, the Company's common stock will trade on a split-adjusted basis.
Why Is Athenex (ATNX) Stock Up 44% Today?
Athenex (NASDAQ: ATNX ) stock is rocketing higher on Tuesday thanks to positive results from a high-risk early-stage breast cancer clinical trial. The Phase 2 study covers the use of the company's oral paclitaxel plus encequidar in combination with a PD-1 inhibitor and carboplatin.
Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer
Oral Paclitaxel combination regimen has graduated in this Phase 2 trial in the triple negative breast cancer subgroup Oral Paclitaxel combination regimen has graduated in this Phase 2 trial in the triple negative breast cancer subgroup
Athenex Announces Positive Results of Special Stockholder Meeting
BUFFALO, N.Y., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the results of its special meeting of stockholders (the “Special Meeting”), held as a virtual meeting on November 22, 2022.
Athenex Announces Closing of the Sale of its China API Business
BUFFALO, N.Y., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the closing of the sale of its equity interests in its China subsidiaries, which primarily represent the Company's ownership of its active pharmaceutical ingredient (API) manufacturing business in China, to Chongqing Comfort Pharmaceutical Inc. (Chongqing Comfort). Chongqing Comfort was assigned the rights and obligations under the Equity Purchase Agreement (Agreement) entered into in July 2022 by TiHe Capital (Beijing) Co. Ltd, pursuant to the terms of the Agreement.
Athenex, Inc. (ATNX) CEO Johnson Lau on Q3 2022 Results - Earnings Call Transcript
Athenex, Inc. (NASDAQ:ATNX ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Tim McCarthy - MD, Investor Relations Johnson Lau - Chief Executive Officer Dan Lang - President, Athenex Cell Therapy Darrel Cohen - Chief Medical Officer, Cell Therapy Jeff Yordon - Chief Operating Officer Joe Annoni - Chief Financial Officer Conference Call Participants Jon Miller - Evercore Yale Jen - Laidlaw & Co Operator Good day, ladies and gentlemen and welcome to the Athenex Third Quarter 2022 Earnings Conference Call. [Operator Instructions] I would now like to hand the conference over to Tim McCarthy, Managing Director of Investor Relations at LifeSci Advisors.
Athenex Announces Receipt of Positive Nasdaq Listing Determination
Nasdaq Hearing Panel grants continued listing of Athenex and extension to regain compliance with the minimum bid price requirement Nasdaq Hearing Panel grants continued listing of Athenex and extension to regain compliance with the minimum bid price requirement
Athenex Provides Third Quarter 2022 Financial Results and Business Update
BUFFALO, N.Y., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today provided a corporate and financial update for the third quarter ended September 30, 2022.
Athenex to Provide Corporate and Financial Update for the Third Quarter 2022 on November 3, 2022
BUFFALO, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the third quarter 2022 on Thursday, November 3, 2022, before the market opens. Athenex's management team will host a conference call and live audio webcast at 8:00 a.m. Eastern Time.
Athenex Files Definitive Proxy Statement for Special Stockholder Meeting
BUFFALO, N.Y., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has filed a definitive proxy statement with the Securities and Exchange Commission in connection with a special meeting of stockholders (the "Special Meeting") scheduled on November 22, 2022 (to be held virtually as a live webcast). The Special Meeting is being held to vote on three matters, including to effect an increase in the total number of authorized shares of common stock of the Company, to effect a reverse stock split of the issued and outstanding shares of common stock, and to increase the number of shares available for issuance under the Company's 2017 Omnibus Incentive Plan. The Company's board of directors has recommended that stockholders vote their shares “FOR” each of the proposals presented at the Special Meeting.
Athenex to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
BUFFALO, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will present at the H.C. Wainwright 24th Annual Global Investment Conference, taking place September 12-14, 2022, in New York, NY and virtually. Company management will also be available for one-on-one investor meetings during the event. Please find additional details about the presentation below.
Athenex, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants
BUFFALO, N.Y., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (“Athenex”) (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the pricing of its underwritten public offering of 35,333,334 shares of its common stock and accompanying warrants to purchase up to 35,333,334 shares of common stock at a combined public offering price of $0.75 per share and accompanying warrant and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 4,666,666 shares of its common stock and accompanying warrants to purchase up to 4,666,666 shares of common stock at a combined public offering price of $0.749 per share and accompanying warrant . The pre-funded warrants have an exercise price of $0.001 per share, are exercisable immediately, and will expire five years following the date of issuance. The warrants have an exercise price of $1.00 per share, are exercisable immediately, and will expire five years following the date of issuance. The gross proceeds to Athenex from the offering, before underwriting discounts and commissions and offering expenses, are expected to be approximately $30 million. The offering is expected to close on August 15, 2022, subject to customary closing conditions.
Athenex, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants
BUFFALO, N.Y., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (“Athenex”) (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock, or pre-funded warrants to purchase common stock in lieu of common stock to certain investors, and accompanying warrants to purchase shares of its common stock, in an underwritten public offering. All of the shares of common stock, warrants and pre-funded warrants are being offered by Athenex.
Athenex, Inc. (ATNX) CEO Johnson Lau on Q2 2022 Results - Earnings Call Transcript
Athenex, Inc. (NASDAQ:ATNX ) Q2 2022 Earnings Conference Call July 28, 2022 8:00 AM ET Company Participants Caileigh Dougherty - Director, Investor Relations Johnson Lau - Chief Executive Officer Dan Lang - President, Athenex Cell Therapy Darrel Cohen - Chief Medical Officer, Cell Therapy Jeff Yordon - Chief Operating Officer Joe Annoni - Chief Financial Officer Conference Call Participants Faisal Khurshid - SVB Securities Jon Miller - Evercore Matt Kaplan - Ladenburg Thalmann Yale Jen - Laidlaw & Co Operator Good day, ladies and gentlemen and welcome to the Second Quarter 2022 Athenex Earnings Conference Call. [Operator Instructions] I would now like to hand the conference over to Caileigh Dougherty, Director of Investor Relations.
Athenex Provides Second Quarter 2022 Financial Results and Business Update
BUFFALO, N.Y., July 28, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today provided a corporate and financial update for the second quarter ended June 30, 2022.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ATNX.